Develop Your Financing Strategy to Attract Capital and Move Beyond Your Initial Seed Stage

Posted April 20, 2018 by OCP | Post a Comment

From the moment you make a decision to set up and operate a business, you’re in the “business lifecycle.” Fasten your seatbelt before the drive as you’ll journey from idea to startup, and if successful, through to the growth and maturity phases. Each stage of the lifecycle has a unique set of obstacles to deal with and overcome. Being flexible in your thinking and adapting your strategy as you move along will serve you well. This not only applies to a business strategy but also to the financial plans to support the development and growth of the Company. A capital financing strategy should summarize investor targets for outreach by stage of the lifecycle, inflection points and how these will change valuation, and the actions to be taken over a three-to-five year period to achieve the company's goals in its business evolution. Putting together the strategy is hard work that takes time and considerable thought. Raising money is also hard work, so get started today.

(more…)

Business Consulting

Objective Capital Partners Adds CardioCell to Expanding Portfolio of Life Science Companies

Posted September 07, 2016 by admin | Post a Comment

Following Positive Results in Phase IIa Heart Failure Clinical Trial,

CardioCell Chooses Objective Capital to Help Manage Rapid Growth

SAN DIEGO – Sept. 7, 2016 – Objective Capital Partners, a leading middle market investment bank and mergers and acquisition (M&A) advisory firm focused on transactions for companies with enterprise values up to $500 million, is pleased to announce that it has recently been retained by CardioCell LLC to help manage its growth needs. CardioCell, a global biotechnology company that uses allogeneic stem cells for cardiovascular indications, recently announced positive data from its Phase IIa clinical trial “Safety and Efficacy of Intravenous Infusion of Ischemia-Tolerant Allogeneic Mesenchymal Stem Cells in Patients With Non-ischemic Cardiomyopathy” at the European Society of Cardiology (ESC) Congress and is currently planning a Phase III study in early 2017.

(more…)

m&A, Business Consulting, Cardiovascular, mergers and acquisitions, Capital Fund Raising, Investment banking, life science, San Diego

Regen BioPharma, Inc. Retains Objective Capital Partners, LLC To Explore Non-Dilutive Funding Opportunities

Posted June 07, 2016 by admin | Post a Comment

San Diego, CA – June 7, 2016- Regen BioPharma, Inc. (OTCQB: RGBP), (OTCQB: RGBPP), announced today that it has retained Objective Capital Partners, LLC as its advisor to assist the company in exploring strategic partnerships, co-development and licensing agreements to enhance shareholder value and provide a source of non-dilutive funding.  The strategies being explored include partnering assets of the Company with the goal to provide a source of non-dilutive funding to primarily support Regen’s NR2F6, tCellVax and small molecule programs.

(more…)

Business Consulting

Objective Capital Partners Advises Marina Biotech on Creating Greater Shareholder Value with the Addition of a Late Stage Clinical Asset

Posted May 17, 2016 by admin | Post a Comment

San Diego, CA and Bothell, WA - May 17, 2016 –  Marina Biotech, Inc. (OTCQB:MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, and Turing Pharmaceuticals AG, a privately-held biopharmaceutical company focused on developing and commercializing innovative treatments for serious diseases, announced that the companies have executed a term sheet under which Marina intends to acquire Turing’s intranasal ketamine program. Pending the negotiation of the definitive agreement, Marina is expected to acquire Turing’s intranasal ketamine program for approximately 53 million Marina common shares. Objective Capital Partners, LLC served as an advisor to Marina Biotech in the transaction.

(more…)

Business Consulting

Objective Capital Partners Closes Deal Capitalization on Tavern+Bowl

Posted May 10, 2016 by admin | Post a Comment

San Diego, CA- May 10, 2016 - Objective Capital Partners, a leading middle market investment bank focused on transactions for companies with enterprise values up to $500 million, is pleased to announce the equity and debt capitalization of Tavern & Bowl, LLC. (Tavern+Bowl), a leading restaurant and hospitality group. Objective Capital Partners served as the lead financial advisor to Tavern+Bowl providing financial leadership from strategic options assessment, through redesigning the capital structure, financial modeling and supporting the capital acquisition.

(more…)

Business Consulting

Objective Capital Partners Retained by Marina Biotech to Explore Strategic Alternatives

Posted February 19, 2016 by admin | Post a Comment

Bothell, WA - February 18, 2016 - Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, announced today that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. The Company has retained Objective Capital Partners, LLC as its exclusive advisor to assist the company in exploring such alternatives. These alternatives will focus on building upon the Company's strong foundation and could include selling, partnering or raising capital to continue growth and development in the business.

(more…)

Business Consulting

Objective Capital Partners Retained by AVACEN Medical Inc. to Explore Strategic Alternatives

Posted February 11, 2016 by admin | Post a Comment

San Diego, CA – February 2, 2016 – AVACEN Medical, a privately held medical device company, announced that its Board of Directors has authorized a process to explore a range of strategic alternatives to enhance shareholder value. The Company has retained Objective Capital Partners, LLC as its exclusive advisor to assist the company in exploring such alternatives. These alternatives, all of which are focused on building upon the Company’s strong foundation, could include selling, partnering or raising capital to continue growth and development in the business.

(more…)

Business Consulting

This article is provided for informational purposes only and does not constitute an offer, invitation or recommendation to buy, sell, subscribe for or issue any securities. While the information provided herein is believed to be accurate and reliable, Objective Capital Partners and BA Securities, LLC makes no representations or warranties, expressed or implied, as to the accuracy or completeness of such information. It should not be construed as investment, legal, or tax advice and may not be reproduced or distributed to any person.

Our Services

Learn about our services and how we can help you sell your business successfully.

LEARN MORE

Contact Us

San Diego Office:
3636 Nobel Dr., Suite 160
San Diego, CA 92122

Los Angeles Office:
10100 Santa Monica Blvd., Suite 300
Los Angeles, CA 90067

Trever Acers
Managing Director
858.663.8662 telephone
trever.acers@objectivecp.com

Channing Hamlet
Managing Director
858.342.4939 telephone
channing.hamlet@objectivecp.com

David H. Crean, Ph.D.
Managing Director
858.461.9490 telephone
david.crean@objectivecp.com

Jack J. Florio
Managing Director
858.864.4339 telephone
jack.florio@objectivecp.com